AR057639A2 - Analogos del peptido 1- similar al glucagon uso de los mismos par ala manufactura de un medicamento y composiciones farmaceuticas que los contienen - Google Patents

Analogos del peptido 1- similar al glucagon uso de los mismos par ala manufactura de un medicamento y composiciones farmaceuticas que los contienen

Info

Publication number
AR057639A2
AR057639A2 ARP070101341A ARP070101341A AR057639A2 AR 057639 A2 AR057639 A2 AR 057639A2 AR P070101341 A ARP070101341 A AR P070101341A AR P070101341 A ARP070101341 A AR P070101341A AR 057639 A2 AR057639 A2 AR 057639A2
Authority
AR
Argentina
Prior art keywords
aib
ala
acc
phe
hglp
Prior art date
Application number
ARP070101341A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR057639A2 publication Critical patent/AR057639A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)

Abstract

Análogos del péptido 1-similar al glucagon y uso de los mismos para la manufactura de un medicamento y composiciones farmacéuticas que los contienen. Reivindicacion 1: Análogos del péptido 1-similar al glucagon, caracterizado porque comprende un compuesto de la siguiente formula (1): (R2R3)-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-39-R1, en la cual, A7 es L-His, Ura, Paa, Pta, Arnp, Tma-His, des-amino-His, o suprimido; A8 es Ala, D-Ala, Acc, N-Me-Ala, N-Me-D-Ala o N-Me-GIy; A9 es Glu, N-Me-Glu, N-Me-Asp o Asp; A10 es Gly, Acc, b-Ala o Aib; A11 es Thr o Ser; A12 es Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, b-Nal, Cha, Trp o X1-Phe; A13 es Thr o Ser; A14 es Ser o Aib; A15 es Asp o Glu; A16 es Val, Acc, Aib, Leu, Ile, TIe, NIe, Abu, Ala o Cha; A17 es Ser o Thr; A18 es Ser o Thr; A19 es Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, b-Nal o X1-Phe; A20 es Leu, Acc, Aib, NIe, Ile, Cha, TIe, Val, Phe o X1-Phe; A21 es Glu o Asp; A22 es Gly, Ace, b-Ala, Glu o Aib; A23 es Gln, Asp, Asn o Glu; A24 es Ala, Aib, Val, Abu, Tle o Acc; A25 es Ala, Aib, Val, Abu, TIe, Acc, Lys, Arg, hArg, Orn, HN-CH((CH2)n-N(R10R11))-C(O) o HN-CH((CH2)e-X3)-C(O); A26 es Lys, Arg, hArg, Orn, HN- CH((CH2)n-N(R10R11))-C(O) o HN-CH((CH2)e-X3)-C(O); A27 es Glu, Asp, Leu, Aib o Lys; A28 es Phe, Pal, b-Nal, X1-Phe, Alo, Aco, Aib, Cha o Trp; A29 es Ile, Acc, Aib, Leu, Nie, Cha, TIe, Val, Abu, Ala o Phe; A30 es Ala, Aib o Acc; A31 es Trp, b-Nal, 3- Pal, 4-Pal, Phe, Acc, Aib o Cha; A32 es Leu, Acc, Aib, Nie, Ile, Cha, Tie, Phe, X1-Phe o Ala; A33 es Val, Acc, Aib, Leu, Ile, TIe, Nle, Cha, Ala, Phe, Abu, Lys o X1-Phe; A34 es Lys, Arg, hArg, Orn, HN-CH((CH2)n-N(R10R11))-C(O) o HN-CH((CH2)e-X3)- C(O); A35 es b-Ala, Aib, D-Ala o a D-Arg; A36 es L- o D-Arg, D- o L-Lys, D- o L-hArg, D- o L-Orn, HN-CH((CH2)n-N(R10R11))-C(O), HN-CH((CH2)e-X3)-C(O) o suprimido; A37 es Gly, b-Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, HN-(CH2)m-C(O), HN- CH((CH2)n-N(R10R11))-C(O), a D-aminoácido o suprimido; A38 es D- o L-Lys, D- o L-Arg, D- o L-hArg, D- o L-Orn, HN-CH((CH2)n-N(R10R11))-C(O), HN-CH((CH2)e-X3)-C(O), Aya, Ado, Aec o suprimido; A39 es O- o L-Lys, O- o L-Arg, HN-CH((CH2)n-N(R10R11))- C(O), Aya, Ado o Aec; X1 para cada ocurrencia es independientemente entre sí, seleccionado de entre el grupo consistente en: alquilo de 1 a 6 átomos de carbono, OH y halo; R1 es OH, NH2, alcoxi C1-30, o NH-X-CH2-Z0, en lo cual X2 es una parte hidrocarburo C1-12, y Z0 es H, OH, CO2H o CONH2; X es un compuesto de formula (2), de formula (3), o -C(O)-NHR, en lo cual X para cada ocurrencia es independientemente entre sí -C(O)-, -NH-C(O)- o -CH2-, y f para cada ocurrencia es independientemente entre sí, un numero entero de 1 a 29 inclusive; cada uno de los R2 y R3 es, independientemente entre sí, seleccionado de entre el grupo consistente en: H, alquilo C1-30, alquenilo C2-30, fenil(C1-30)alquilo, naftil(C1-30)alquilo, hidroxi-alquilo C1-30, hidroxialquenilo C2-30, hidroxifenilalquilo C1-30, e hidroxinaftilalquilo C1-30: o, uno de R2 y R3 es un compuesto de formula (4), acilo C1-30, alquilsulfonilo C1-30, C(O)X, o de formula (5) o (6); en lo cual Y es H, OH o NH2; r vale de 0 a 4; q vale de 0 a 4; y X5 es alquilo C1-30, alquenilo C2-30, fenilalquilo C1-30, naftilalquilo C1-30, hidroxialquilo C1-30, hidroxialquenilo C2-30, hidroxifenilalquilo C1-30 o hidroxinaftilalquilo C1-30; e es, independientemente entre sí, en cada ocurrencia un numero entero de 1 a 4 inclusive; m es, independientemente entre sí, en cada ocurrencia un numero entero de 5 a 24 inclusive; n es, independientemente entre sí, en cada ocurrencia un numero entero de 1 a 5 inclusive; R10 y R11 para cada ocurrencia es, cada uno de ellos e independientemente entre sí, H, alquilo C1-30, acilo C1-30, alquilsulfonilo C1-30, -C((NH)(NH2)) o un compuesto de formula (7); y R12 y R13 son, cada uno de ellos e independientemente entre sí, alquilo C1-30; con la condicion que cuando A7 es Ura, Paa o Pta, entonces R2 y R3 están suprimidos; cuando R10 es acilo C1-30, alquilsulfonilo C1-30, -C((NH)(NH2)) o el resto de formula (7), entonces R11 es H o alquilo C1-30; (i) por lo menos un aminoácido de un compuesto de la formula (1) no es el mismo que la secuencia nativa de hGLP-1 (7-36, -37 o -38)NH2 o hGLP-1 (7-36, -37 o -38)OH; (ii) un compuesto de la formula (1) no es un análogo de hGLP-1 (7-36, -37 o -38)NH o hGLP-1 (7-36, -37 o -38)OH en lo cual una unica posicion ha sido sustituida por Ala; (iii) un compuesto de la formula (1) no es (Arg26, 34, Lys38)hGLP-1(7-38)-E, (Lys26(Ne-alcanoil))hGLP1 (7-36, -37 o -38)-E, (Lys34(Ne-alcanoil))hGLP1 (7-36, -37 o -38)-E, (Lys26,34bis(Ne?-alcanoil))hGLP1 (7-36, -37 o -38)-E, (Arg26, Lys34(Ne?alcanoil))hGLP-1 (8-36, -37 o -38)-E, (Arg26,34, Lys36(Ne?-alcanoil))hGLP1 (7-36, -37 o -38)-E o (Arg26,34, Lys38(Ne-alcanoil))hGLP-1(7-38)-E, siendo E, -OH o -NH2; (iv) un compuesto de la formula (1) no es Z1-hGLP-1 (7-36, -37 o -38)-OH, Z1hGLP(7-36, -37 o -38)-NH2, estando Z1 seleccionado de entre el grupo consistente en: (e) (Arg26), (Arg34), (Arg26,34), (Lys36), (Arg26, Lys36), (Arg24, Lys36), (D-Lys36), (Arg36), (D-Arg36), (Arg26,34, Lys36) o (Arg26,36, Lys34); (f) (Asp21); (g) por lo menos uno de los siguientes: (Aib8), (D-Ala8) y (Asp9); y (h) (Tyr7), (N-acil-His7), (N-alquil-His7), (N-acil-D-His7) o (N-alquil-D-His7); (v) un compuesto de la formula (1) no es una combinacion de dos cualesquiera de las sustituciones enumeradas en los grupos (a) a (d); y (vi) un compuesto de la formula (1) no es (N-Me-Ala8)hGLP-1(8-36 o -37), (Glu15)hGLP-1(7-36 o -37), (Asp21)hGLP-1(7-36 o -37) o (Phe31)hGLP-1(7-36 o -37) o una sal farmacéuticamente aceptable del mismo; con la condicion que el compuesto no es (Aib8, 35)hGLP-1(7-36)NH2.
ARP070101341A 1998-12-07 2007-03-29 Analogos del peptido 1- similar al glucagon uso de los mismos par ala manufactura de un medicamento y composiciones farmaceuticas que los contienen AR057639A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20660198A 1998-12-07 1998-12-07

Publications (1)

Publication Number Publication Date
AR057639A2 true AR057639A2 (es) 2007-12-12

Family

ID=32592693

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP990106236A AR021576A1 (es) 1998-12-07 1999-12-07 Analogos del peptido 1-similar al glucagon, uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen.
ARP030101524A AR040228A2 (es) 1998-12-07 2003-04-30 Analogos del peptido 1-similar al glucagon uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen
ARP070101341A AR057639A2 (es) 1998-12-07 2007-03-29 Analogos del peptido 1- similar al glucagon uso de los mismos par ala manufactura de un medicamento y composiciones farmaceuticas que los contienen
ARP100101943A AR076950A2 (es) 1998-12-07 2010-06-02 Analogos del peptido 1-similar al glucagon uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP990106236A AR021576A1 (es) 1998-12-07 1999-12-07 Analogos del peptido 1-similar al glucagon, uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen.
ARP030101524A AR040228A2 (es) 1998-12-07 2003-04-30 Analogos del peptido 1-similar al glucagon uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP100101943A AR076950A2 (es) 1998-12-07 2010-06-02 Analogos del peptido 1-similar al glucagon uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen

Country Status (7)

Country Link
EP (1) EP1359159A3 (es)
CN (1) CN1935839B (es)
AR (4) AR021576A1 (es)
CA (1) CA2778047A1 (es)
DK (1) DK1137667T3 (es)
PL (1) PL189664B1 (es)
ZA (2) ZA200304047B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066207A1 (en) * 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
MX339137B (es) 2008-08-07 2016-05-13 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal.
US9072703B2 (en) 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
CN104968674A (zh) * 2012-12-19 2015-10-07 诺和诺德股份有限公司 具有胆固醇流出活性的新颖的glp-1受体激动剂
AR104932A1 (es) * 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
EP1826216A1 (en) * 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція

Also Published As

Publication number Publication date
AR040228A2 (es) 2005-03-23
ZA200104478B (en) 2003-12-01
PL189664B1 (pl) 2005-09-30
CN1935839A (zh) 2007-03-28
DK1137667T3 (da) 2005-02-14
ZA200304047B (en) 2004-04-28
CN1935839B (zh) 2012-06-06
EP1359159A2 (en) 2003-11-05
AR021576A1 (es) 2002-07-24
CA2778047A1 (en) 2000-06-15
EP1359159A3 (en) 2004-07-21
AR076950A2 (es) 2011-07-20

Similar Documents

Publication Publication Date Title
CA2353574A1 (en) Analogues of glp-1
RU2001118855A (ru) Аналоги glp-1
RU2208015C2 (ru) Аналоги гпп-1
AR043365A1 (es) Analogos del glp-1
KR920700226A (ko) 선형 소마토스타틴 유사체
AR019131A1 (es) Analogos de polipeptidos pituitarios que activan la adenilato ciclasa, una composicion farmaceutica que los comprende, y el uso de dichos peptidos para lamanufactura de un medicamento
KR960703015A (ko) 후천성 면역결핍증 치료용 약물의 제조시 노나- 및 데카펩타이드의 용도(Use of nona-and decapeptides in the preparation of a durg for the treatment of AIDS)
RU2001118839A (ru) Аналоги гпп-1
AR076950A2 (es) Analogos del peptido 1-similar al glucagon uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen
AU2560695A (en) A pharmaceutical preparation comprising glucagon
KR950702578A (ko) 파라티로이드 호르몬(pth) 및 파라티로이드 호르몬 관련 펩티드(pthrp)의 유사체, 이들의 합성 및 골다공증 치료를 위한 이들의 용도(analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis)
BRPI0607039A2 (pt) formulação, forma de dosagem unitária, uso de uma formulação, produto farmacêutico e, método para a preparação de um produto farmacêutico
RU2008104802A (ru) Лиганды рецепторов меланокортинов
JP2005530732A5 (es)
JP2002509854A5 (es)
AR066175A1 (es) Ligandos del receptor de melanocortina de peptidos ciclicos
FI93308B (fi) Menetelmä somatostatiinia sisältävän farmaseuttisen ainekoostumuksen valmistamiseksi
ES2676065T3 (es) Nuevo derivado de un análogo de la insulina
EP4364751A3 (en) Novel glp-1 analogues
ES2253353T3 (es) Reduccion del colesterol serico.
KR20140093967A (ko) 질병 및 장애 치료용 펩타이드 유사체
DK1014948T3 (da) Lyofiliseret farmaceutisk præparat som er beregnet til at efterligne et lægemiddel på basis af proteiner eller polypeptider
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
JP2015503512A5 (es)
AU2021399904B2 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
FG Grant, registration